James R. Kasinger, the General Counsel and Secretary of CRISPR Therapeutics AG, has reported several stock transactions in a recent SEC filing. This activity includes the acquisition of shares and sales to cover tax obligations related to restricted stock units. Such transactions are significant as they reflect the ongoing financial management and compliance efforts within the company.
Background
CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines for serious diseases. The company operates under the SIC code 2836, which pertains to Biological Products (No Diagnostic Substances). CRISPR is known for its innovative approaches in the life sciences sector, utilizing CRISPR/Cas9 technology for gene editing. The company is publicly traded under the ticker symbol CRSP, and its business operations are based in Zug, Switzerland.
What the Filing Says
According to the filing dated October 15, 2026, Kasinger reported two notable transactions. On October 13, he acquired 2,113 common shares through a transaction coded as 'M' for acquisition. The following day, he sold 1,040 shares at a price of $49.26 to cover tax withholding obligations related to the vesting of restricted stock units. The filing states, "This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person." Following these transactions, Kasinger holds a total of 95,857 shares.
Impact
This update may impact CRISPR Therapeutics' stakeholders, including investors and employees, as it highlights the financial activities of key executives. Such transparency is crucial in maintaining trust and compliance within the biotechnology sector. The ongoing transactions also indicate a proactive approach to managing stock options and tax obligations, which can be a point of interest for other companies in the biological products industry.
What's Next
The filing does not say what happens next.